Clinical Decision Making in Advanced NSCLC without Actionable Mutations
Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.
Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5